Denosumab: differenze tra le versioni

Versione delle 20:19, 9 gen 2012

Versione delle 17:12, 12 gen 2012

Riga 81:

* [[Anticorpi monoclonali (uso clinico approvato)]]

| name = {{Anticorpi monoclonali per il sistema immune}}

== Collegamenti esterni ==

|name = {{Anticorpi monoclonali per i tumori }}

*

{{Navbox

| name = Anticorpi monoclonali per il sistema immune

| title = [[Anticorpi monoclonali]] per il [[sistema immune]]

| groupstyle = background-color: LightGreen

| group1 = [[Sistema immune]]<br /> ("-l(i[m])-")

| list1 = {{Navbox subgroup

| group1 = Umani<br /> ("-limu-")

| list1 = ''[[immunosuppressione]]'': [[Adalimumab]]&nbsp;• [[Atorolimumab]]&nbsp;• [[Fresolimumab]]&nbsp;• [[Golimumab]]&nbsp;• [[Lerdelimumab]]&nbsp;• [[Metelimumab]]&nbsp;• [[Morolimumab]]

''Attivazione immunitaria'': [[Ipilimumab]]&nbsp;• [[Tremelimumab]]

''Altri'': [[Bertilimumab]]&nbsp;• [[Zanolimumab]]

| group2 = Topo<br /> ("-limo-")

| list2 = [[Afelimomab]]&nbsp;• [[Elsilimomab]]&nbsp;• [[Faralimomab]]&nbsp;• [[Gavilimomab]]&nbsp;• [[Inolimomab]]&nbsp;• [[Maslimomab]]&nbsp;• [[Nerelimomab]]&nbsp;• [[Odulimomab]]&nbsp;• [[Telimomab aritox]]&nbsp;• [[Vepalimomab]]&nbsp;• [[Zolimomab aritox]]

| group3 = [[Anticorpo chimerico|Chimerici]]<br /> ("-lixi-")

| list3 = [[Basiliximab]]&nbsp;• [[Clenoliximab]]&nbsp;• [[Galiximab]]&nbsp;• [[Gomiliximab]]&nbsp;• [[Infliximab]]&nbsp;• [[Keliximab]]&nbsp;• [[Lumiliximab]]&nbsp;• [[Priliximab]]&nbsp;• [[Teneliximab]]&nbsp;• [[Vapaliximab]]

| group4 = [[Anticorpo umanizzato|Umanizzato]]<br /> ("-lizu-")

| list4 = ''immunosuppressive:'' [[Aselizumab]]&nbsp;• [[Apolizumab]]&nbsp;• [[Benralizumab]]^†&nbsp;• [[Cedelizumab]]&nbsp;• [[Certolizumab pegol]]&nbsp;• [[Daclizumab]]&nbsp;• [[Eculizumab]]&nbsp;• [[Efalizumab]]&nbsp;• [[Epratuzumab]]&nbsp;• [[Erlizumab]]&nbsp;• [[Fontolizumab]]&nbsp;• [[Mepolizumab]]&nbsp;• [[Natalizumab]]&nbsp;• [[Ocrelizumab]]&nbsp;• [[Omalizumab]]&nbsp;• [[Pascolizumab]]&nbsp;• [[Pexelizumab]]&nbsp;• [[PRO 140]]^†&nbsp;• [[Reslizumab]]&nbsp;• [[Rontalizumab]]&nbsp;• [[Rovelizumab]]&nbsp;• [[Ruplizumab]]&nbsp;• [[Siplizumab]]&nbsp;• [[Talizumab]]&nbsp;• [[Teplizumab]]&nbsp;• [[Tocilizumab]]&nbsp;• [[Toralizumab]]&nbsp;• [[Vedolizumab]]&nbsp;• [[Visilizumab]]&nbsp;• [[TGN1412]]^§<br/>''non-immunosuppressive:''[[Ibalizumab]]^†

| group5 = Chimerici + umanizzati<br />("-lixizu-")

| list5 = [[Dorlixizumab]]&nbsp;• [[Otelixizumab]]

}}

| group2 = [[Interleukina]]<br /> ("-k(i[n])-")

| list2 = {{Navbox subgroup

| group1 = Umani<br /> ("-kinu-")

| list1 = [[Briakinumab]]&nbsp;• [[Canakinumab]]&nbsp;• [[Ustekinumab]]

| group2 = Umanizzati<br /> ("-kizu-")

| list2 = [[Lebrikizumab]]

}}

| group11 = Inflammatorie [[lesioni]]<br /> ("-les-")

| list11 = {{Navbox subgroup

| group1 = topo<br /> ("-leso-")

| list1 = [[Besilesomab]]&nbsp;• [[Technetium (99mTc) fanolesomab|Fanolesomab]]^‡&nbsp;• [[Lemalesomab]]&nbsp;• [[Technetium (99mTc) sulesomab|Sulesomab]]

}}

| belowstyle = background: transparent; padding: 0px;

| below = {{PharmNavFootnote}}{{Lymph cell navs}}

}}

{{Navbox

|name = Anticorpi monoclonali per i tumori

|title = [[Anticorpi monoclonali]] per i tumori

|image =

|above =

| group3 = [[Tumore]]<br /> ("-t(u[m])-")

| list3 = {{Navbox subgroup

| group1 = Umano<br /> ("-tumu-")

| list1 = [[Adecatumumab]]&nbsp;• [[Belimumab]]&nbsp;• [[Cixutumumab]]&nbsp;• [[Conatumumab]]&nbsp;• [[Figitumumab]]&nbsp;• [[Glembatumumab vedotin]]&nbsp;• [[Iratumumab]]&nbsp;• [[Lexatumumab]]&nbsp;• [[Lucatumumab]]&nbsp;• [[Mapatumumab]]&nbsp;• [[Necitumumab]]&nbsp;• [[Ofatumumab]]&nbsp;• [[Olaratumab]]&nbsp;• [[Panitumumab]]&nbsp;• [[Pritumumab]]&nbsp;• [[Robatumumab]]&nbsp;• [[Technetium (99mTc) votumumab|Votumumab]]&nbsp;• [[Zalutumumab]]

| group2 = Topo<br /> ("-tumo-")

| list2 = [[Indium (111In) altumomab pentetate|Altumomab pentetate]]&nbsp;• [[Anatumomab mafenatox]]&nbsp;• [[Technetium (99mTc) arcitumomab|Arcitumomab]]&nbsp;• [[Bectumomab]]&nbsp;• [[Blinatumomab]]&nbsp;• [[Iodine (125I) CC49|CC49]]&nbsp;• [[Detumomab]]&nbsp;• [[Ibritumomab tiuxetan]]&nbsp;• [[Minretumomab]]&nbsp;• [[Mitumomab]]&nbsp;• [[Naptumomab estafenatox]]&nbsp;• [[Technetium (99mTc) nofetumomab merpentan|Nofetumomab merpentan]]&nbsp;• [[Pemtumomab]]&nbsp;• [[Technetium (99mTc) pintumomab|Pintumomab]]&nbsp;• [[Indium (111In) satumomab pendetide|Satumomab pendetide]]&nbsp;• [[Taplitumomab paptox]]&nbsp;• [[Tenatumomab]]&nbsp;• [[Tositumomab]]&nbsp;• [[3F8]]

"-govo-" ([[Tumore dell'ovaio]]): [[Abagovomab]]&nbsp;• [[Indium (111In) igovomab|Igovomab]]&nbsp;• [[Oregovomab]]

"-pro-" ([[Carcinoma della prostata|Tumore prostatico]]): [[Indium (111In) capromab pendetide|Capromab pendetide]]

"-colo-" ([[Tumore del colon]]): [[Edrecolomab]]&nbsp;• [[Nacolomab tafenatox]]

| group3 = [[anticorpo chimerico|Chimerico]]<br /> ("-tuxi-")

| list3 = [[Bavituximab]]&nbsp;• [[Brentuximab vedotin]]&nbsp;• [[Cetuximab]]&nbsp;• [[Siltuximab]]&nbsp;• [[Rituximab]]<br />

"-mexi-" ([[Melanoma]]): [[Ecromeximab]]

| group4 = [[Anticorpo umanizzato|Umanizzato]]<br /> ("-tuzu-")

| list4 = [[Afutuzumab]]&nbsp;• [[Alemtuzumab]]&nbsp;• [[Bevacizumab]]&nbsp;• [[Bivatuzumab mertansine]]&nbsp;• [[Cantuzumab mertansine]]&nbsp;• [[Citatuzumab bogatox]]&nbsp;• [[Dacetuzumab]]&nbsp;• [[Elotuzumab]]^†&nbsp;• [[Etaracizumab]]&nbsp;• [[Farletuzumab]]&nbsp;• [[Gemtuzumab ozogamicin]]&nbsp;• [[Inotuzumab ozogamicin]]&nbsp;• [[Labetuzumab]]&nbsp;• [[Lintuzumab]]&nbsp;• [[Matuzumab]]^§&nbsp;• [[Milatuzumab]]&nbsp;• [[Nimotuzumab]]&nbsp;• [[Oportuzumab monatox]]&nbsp;• [[Pertuzumab]]&nbsp;• [[Sibrotuzumab]]&nbsp;• [[Tacatuzumab tetraxetan]]&nbsp;• [[Tigatuzumab]]&nbsp;• [[Trastuzumab]]&nbsp;• [[Tucotuzumab celmoleukin]]&nbsp;• [[Veltuzumab]]

| group5 = [[Anticorpi trifunctionali|Ratto/topo ibrido]]<br /> ("-tumaxo-")

| list5 = [[Catumaxomab]]&nbsp;• [[Ertumaxomab]]

}}

| below = {{PharmNavFootnote}}

}}

{{Portale|medicina}}